MIND Diet and Cognitive Function in Middle-aged and Older Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shandong
-
Taian, Shandong, China, 271000
- Mutiple Counties
-
Principal Investigator:
- Changzheng Yuan, ScD
-
Contact:
- Changzheng Yuan, ScD
- Phone Number: (86)17326860291
- Email: chy478@zju.edu.cn
-
Sub-Investigator:
- Tao Zhang, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Normal chewing function, able to eat hard foods such as nuts.
- Willing to participate and sign an informed consent form.
- Able to understand research procedures and adhere to them throughout the entire study period.
Exclusion Criteria:
- Participation in or have participated in other clinical trial studies within the past year.
- Medication to treat Alzheimer's or Parkinson's disease.
- Diagnosis of severe chronic diseases, such as cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Control arm
General dietary advice
|
Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.
|
|
Active Comparator: Intervention arm
MIND diet education
|
Participants will be given three MIND diet education videos on different topics at baseline and during follow-up.
In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in 5-min Montreal Cognitive Assessment (MoCA) score
Time Frame: 12 months
|
Cognitive function will be assessed using the MoCA at baseline and during follow-up.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in EuroQol Five Dimensions (EQ-5D) scale
Time Frame: 12 months
|
The 5-level EQ-5D (EQ-5D-5L) will be used to assess life quality.
Evaluations will be conducted at baseline and during follow-up.
|
12 months
|
|
Change in 8-Item Alzheimer's Diseases Screening Tool (AD-8) score
Time Frame: 12 months
|
AD-8 will be used to assess cognitive function.
Evaluations will be conducted at baseline and during follow-up.
|
12 months
|
|
Change in Mediterranean-Dietary Approach to Stop Hypertension (DASH) Intervention for Neurodegenerative Delay (MIND) diet score
Time Frame: 12 months
|
Dietary behavior will be assessed using food frequency questionnaire (FFQ).
A 15-point MIND diet score will be calculated to reflect the MIND diet adherence among both groups of participants.
Evaluations will be conducted at baseline and during follow-up.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LL20240353
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.